Biotech | December 09, 2025
AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Patients can now get the starting 2.5 mg dose for $299 per month
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Subscribe To Our Newsletter & Stay Updated
